Modular Medical, Inc. · NASDAQ:MODD
Modular Medical — Investor Presentation (March 2021)
23 slides from Modular Medical's investor presentation, Mar 25, 2021
Slide 1: Modular Medical Investor Presentation
MODULAR MEDICAL Investor Presentation. OTCQB:MODD
Slide 2: Forward Looking Statements, Other Disclaimers
Forward Looking Statements, Other Disclaimers. THIS SUMMARY IS PROVIDED ON A CONFIDENTIAL AND LIMITED BASIS, SOLELY FOR YOUR USE AS A PART OF YOUR DETERMINATION OF WHETHER TO INVEST IN THE OPPORTUNITY. THIS SUMMARY IS BEING PROVIDED IN RELIANCE UPON SECTION 105(C) OF THE JUMPSTART OUR BUSINESS START
Slide 3: Diabetes Care for the Rest of Us
Diabetes Care for the Rest of Us. Despite decades of advances in insulin delivery technology, only a minority of individuals with Type 1 diabetes use a pump. The cost and complexity of today’s offerings mean that, for many, multiple daily injections remain the only practical solution. At Modular Med
Slide 4: The Future of Diabetes Care is Easy
Type l’s in US 1.6 Million Cpj MODULAR MEDICAL The Future of Diabetes Care is Easy. Insulin Pumps provide a higher standard of diabetes care. Better glycemic control reduces co-morbidity prevalence, trips to the ER, and leads to higher quality of life. People with Type 1 Diabetes are a cross section
Slide 5: An Unmet Need in Type 1 Diabetes Care
I © MODULAR MEDICAL An Unmet Need in Type 1 Diabetes Care. There are 1.6 million individuals with Type 1 Diabetes in the US. 100% of patient population require daily insulin injection. Only 1 out of 3 currently use an insulin pump. Pumping 32% of population utilizes insulin pumps for diabetes manage
Slide 6: Time to Change
Time Insulin pumps on the market today require a substantial amount of time to manage therapy Money High out of pocket costs of today’s pumps place these technologies out of reach for a large part of the population Technology Feature-heavy and complex systems have hampered adoption. These products a
Slide 7: Encouraging Adoption
Encouraging Adoption. Abbott Libre Freestyle made continuous glucose monitoring easier and more affordable. This expanded the product category and doubled its size. We believe the insulin pump market is ready for a similar transition. “In short, Flash Glucose Monitoring is fundamentally trying to ta
Slide 8: Three Standards
I MODULAR MEDICAL Three Standards. All drugs and medical devices must meet three standards ? ? ? Viable The product must be desired by the market: feature and cost competitive, attractive to users. Approvable The product must be approvable by the FDA: meets all testing and regulatory requirements an
Slide 9: Viable. Introducing Pivot
Viable. Introducing Pivot 180 Day Reusable 3 Day Consumable Remove the trade off between high cost and complexity and high-quality care: expand market by meeting unmet needs. Features & Benefits: Removable No External Controller Required Push Button to Bolus No Charging or Battery Replacement Easy t
Slide 10: Approvable
Approvable. Approval: 510(k) Predicate device approval pathway for FDA label. Same label as Omnipod. Testing is based on benchtop tests, no human trials required (no insulin pump has done pre-approval human trials) Submission: First FDA meeting was held in Nov. 2019. Second meeting was Mar. 2020. FD
Slide 11: Profitable
Profitable. New microfluidics technology allows for low-cost pumping of insulin. New design philosophy makes product simple enough for provider driven sales. Traditional Pumps Use Expensive Machining and Complex Modalities To Pump Insulin 5 Years Development: Same Precision, Off the Shelf, High Volu
Slide 12: Unit Economics. Profitable From the First Sale
180 Day Re-Usable Price: FREE Cost: $34 3 Day Disposable Price: $34.92* Cost: $7.68 *Omnipod CPT code with 20% discount MODULAR MEDICAL Unit Economics. Profitable From the First Sale First month: 1 Re-Usable + 10 Disposables Price: $349.20 Cost: $34 + $76.80 = $111.80 Gross Profit: $238.40 68% Profi
Slide 13: Designed with the Patient & Provider in Mind
13 I 0i Designed with the Patient &Provider in Mind. - Provider - Direct sales Force Focused on Providers Free Samples to Encourage Trial Point of Prescription Couponing Simple to Teach and Support Patients - Patient — Only product that you can take home today from doctor’s office App to Learn Produ
Slide 14: Payor Preferred
Payor Preferred. Modular Medical products are designed to attain preferential reimbursement and avoid the coverage pitfalls many other pumps have experienced. Payor Benefits: 20% Discount vs Insulet (PODD) Will Drive Preferred Status Designed to use PBM codes as a disposable No New Code: Reimbursed
Slide 15: T1D Insulin Pump Comparisons (US Market)
T1D Insulin Pump Comparisons (US Market). Product Features Manufacturer t:slim X2 Medtronic 780G Tandem Diabetes Care Medtronic (MiniMed) Reservoir Size 300 units/3mL 300 units/3mL Pump Cost Monitorable Via User’s Cell Phone User Interface External Controller Required Pump: $4,200 Disposables: $134/
Slide 16: Product Roadmap. The Path to the Artificial Pancreas
Product Roadmap. The Path to the Artificial Pancreas (Cell phone controlled adjusted by algorithm) Pivot G-3 (Autonomous, multiple chamber, drug revenue)
Slide 17: In Development Pivot G-2
In Development Pivot G-2. Enhanced Modular Patch Pump: Cell Phone Controlled 2-Factor Authentication Allows use of user’s own cell phone as controller. No dedicated controller required. CGM Integration Allows algorithms to adjust basal rate for meals and exercise. Ease of Use Same modular design and
Slide 18: The Future of Care Pivot G-3
The Future of Care Pivot G-3. The Pivot G-3 is a native multi-chamber pump developed with enhanced ease of use in mind. Designed to be prefilled, the Pivot G-3 will enabl Modular Medical to capture drug revenue. Modular Medical will become the one-stop shop for all of a user’s diabetes needs. Pivot
Slide 19: The Team
The Team. CEO Paul DiPerna 30 years of experience in medical device industry Led over 10 projects to FDA approval Founder Tandem Diabetes (TNDM:NAS) Designer and lead developer of t:slim pump, a leading insulin pump in type 1 diabetes Founder and CEO, Modular Medical: an innovative next generation i
Slide 20: Financial Highlights
(s)hÔdÛÜr MEDICAL Financial Highlights. Stock Information Listing OTC Symbol MODD Share Structure (as of March 22, 2021) Shares Outstanding 18.9 M Price Per Share $4.50 Market Cap $85.1 M Executive &Insider Ownership 74%
Slide 21: Investor Relations
MODULAR MEDICAL Investor Relations r@modular-medical.com OTCQB:MODD
Slide 22: Appendix
Appendix.
Slide 23: Artificial Pancreas Will Be Multi-Chamber
(s)hÔdÛÜr MEDICAL Artificial Pancreas Will Be Multi-Chamber. FDA has established 70% Time In Range “no human intervention” standard for AR “Control IQ” study published in NE Journal of medicine barely reached 70% despite announcing meals, sleep, and exercise. Prominent KOL’s and Algo designers feel